Sutro Biopharma, Inc. - STRO STOCK NEWS

Sutro Biopharma (NASDAQ: STRO) announced advancements in its novel immunostimulatory antibody-drug conjugate (iADC) modality at the 12th Annual World ADC conference held in London from March 29 to April 1, 2022. This innovative approach uses a dual mechanism to target tumors, leveraging a cytotoxic warhead and a toll-like receptor (TLR) agonist to activate the immune system. Presentations featured data on STRO-002, aimed at treating ovarian and endometrial cancers, which has received Fast Track designation from the FDA. Sutro aims to develop therapies that address unmet needs in oncology.

Sutro Biopharma (NASDAQ: STRO) announced that CEO Bill Newell will participate in the Ovarian Cancer Panel at the Cowen 42nd Annual Healthcare Conference on March 9, 2022, at 12:50 p.m. ET. A live webcast can be accessed on the company's website, with a replay available for 30 days. Sutro is focused on cancer therapeutics through its platforms XpressCF® and XpressCF+™, which led to drug candidates like STRO-001 and STRO-002, both in clinical trials with FDA designations. Sutro is dedicated to improving cancer treatment for patients.

Sutro Biopharma (STRO) reported a strong performance for 2021, with revenue increasing to $61.9 million from $42.7 million in 2020, driven by collaborations with Merck, BMS, and EMD Serono. The company is advancing its lead candidate, STRO-002, which targets ovarian cancer, completing its Phase 1 trial enrollment and planning a registrational path forward. However, operating expenses rose to $160.4 million, up from $113.8 million, partly due to stock-based compensation. Sutro's cash reserves stood at $229.5 million, providing runway into late 2023.

Sutro Biopharma (NASDAQ: STRO), a clinical-stage company based in South San Francisco, announced that CEO Bill Newell will present at the 40th Annual J.P. Morgan Healthcare Conference on January 13, 2022, at 11:15 a.m. ET. The live presentation will be available via webcast on the company's website. Sutro focuses on advanced oncology therapeutics, using its XpressCF® platform to develop candidates like STRO-001 and STRO-002, currently in clinical trials for B-cell malignancies and ovarian cancer, respectively.

Sutro Biopharma (NASDAQ: STRO) announced interim results from its Phase 1 study of STRO-002, a folate receptor alpha-targeting ADC for advanced ovarian cancer. The study, involving 44 patients with extensive prior treatments, reported an overall response rate (ORR) of 33%. Notably, patients starting at a 5.2 mg/kg dose level exhibited a 47% ORR. Encouraging safety signals included no new complications. Sutro plans to advance STRO-002 into further clinical phases, leveraging its Fast Track designation.

Sutro Biopharma (NASDAQ: STRO) has entered an exclusive license agreement with Tasly Biopharmaceuticals for the development and commercialization of STRO-002 in Greater China, which includes mainland China, Hong Kong, Macau, and Taiwan. Sutro will receive an upfront payment of $40 million and could earn up to $345 million in milestone payments. STRO-002 is currently in clinical trials for ovarian and endometrial cancers. Sutro retains rights outside of Greater China and will receive royalties based on STRO-002's net sales.

Sutro Biopharma (STRO) announced a KOL virtual event on Jan. 5, 2022, to share interim data from the Phase 1 study of STRO-002, an antibody-drug conjugate for advanced ovarian cancer. The trial, which enrolled 44 patients by Nov. 2021, aims to assess the efficacy, safety, and tolerability of STRO-002 in patients who have undergone multiple prior therapies. The event will feature presentations from Sutro management and Dr. R. Wendel Naumann from the Levine Cancer Institute.

Sutro Biopharma (NASDAQ: STRO) announced new nonclinical data for STRO-002 and STRO-001 presented at the ASH 2021 conference, showcasing potential therapies for acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Research led by Fred Hutchinson Cancer Research Center identifies FOLR1 and CD74 as actionable targets. STRO-002 exhibited strong efficacy against high-risk AML subtypes, while STRO-001 demonstrated significant cytotoxicity in both AML and ALL cells. The data supports ongoing clinical trials for both products in treating various cancer indications.

Sutro Biopharma (NASDAQ: STRO) announced CEO Bill Newell's participation in two virtual investor conferences. The Piper Sandler 33rd Annual Healthcare Conference is scheduled for November 22, 2021, at 10:00 a.m. ET, featuring a pre-recorded fireside chat. The 4th Annual Evercore ISI HealthCONx Conference will take place on November 30, 2021, at 10:05 a.m. ET, with a live fireside chat. Webcasts are accessible via Sutro's Investor Relations page, with archived replays available for 30 days.